Osimertinib GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
This is an open label, phase II study to assess the efficacy of osimertinib (80 mg, orally,
once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical
resection for actionable EGFR mutation-positive stage IB-IIIA lung adenocarcinoma.